---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-019256"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:03:55.519519+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Aligos Therapeutics appoints Lesley Ann Calhoun as COO while retaining CFO role

## Summary
- Lesley Ann Calhoun appointed COO effective January 30, 2025, adding to existing CFO role.
- She has served as EVP and CFO since June 2020; prior roles at Global Blood Therapeutics and Hyperion Therapeutics.
- Calhoun brings over 30 years of finance and operations experience, including audit at Deloitte & Touche.

## SEC filing metadata
- accession: 0001193125-25-019256
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312525019256/0001193125-25-019256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312525019256/d860038d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-019256
- JSON: https://secwatch.observer/filing/0001193125-25-019256.json
- Plain text: https://secwatch.observer/filing/0001193125-25-019256.txt

## Key facts
- Executive change
  Lesley Ann Calhoun was appointed as Chief Operating Officer at Aligos Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On January 30, 2025, the Board of Directors of Aligos Therapeutics, Inc. (the “Company”) appointed Lesley Ann Calhoun as the Company’s Chief Operating Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000119312525019256/0001193125-25-019256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.